{"title":"Development of ion-triggered <i>in situ</i> gel containing ketoconazole/hydroxypropyl-β-cyclodextrin for ocular delivery: <i>in vitro</i> and <i>in vivo</i> evaluation.","authors":"Huiyun Xia, Jingjing Yang, Fei Song, Guojuan Pu, Fudan Dong, Zhen Liang, Junjie Zhang","doi":"10.1080/10717544.2024.2424217","DOIUrl":"10.1080/10717544.2024.2424217","url":null,"abstract":"<p><p>The application of ketoconazole (KET) in ocular drug delivery is restricted by its poor aqueous solubility though its broad-spectrum antifungal activity. The aim of this study is to develop an ion-sensitive <i>in situ</i> gel (ISG) of KET to promote its ocular bioavailability in topical application. The solubility of KET in water was increased by complexation with hydroxypropyl-β-cyclodextrin (HPβCD), then KET-HPβCD inclusion complex (KET-IC) was fabricated into an ion-sensitive ISG triggered by sodium alginate (SA). The <i>in vitro</i> drug release and antifungal activities investigations demonstrated that the KET-IC-ISG formulation increased drug release and anti-fungal activities compared to pure KET. The <i>ex vivo</i> rabbit corneal permeation studied demonstrated higher permeability of KET-IC-ISG formulation (<i>P<sub>app</sub></i> of (6.34 <math><mrow><mo>±</mo></mrow></math>0.21) <math><mrow><mo>×</mo></mrow></math>10<sup>-4 </sup>cm/h) than pure KET (<i>P<sub>app</sub></i> of (3.09 <math><mrow><mo>±</mo></mrow></math> 0.09) <math><mrow><mo>×</mo></mrow></math>10<sup>-4 </sup>cm/h). The cytotoxicity assay and the ocular irritation study in rabbits confirmed the KET-IC-ISG safety and well tolerance. The ocular pharmacokinetics of KET in rabbits was investigated and the results showed that the KET-IC-ISG increased its bioavailability in cornea by 47-fold. In conclusion, the KET-IC-ISG system promoted the precorneal retention, the ocular drug bioavailability and the developed formulation is a potential strategy to treat mycotic keratitis.</p>","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"31 1","pages":"2424217"},"PeriodicalIF":6.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11562027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Breaking boundaries: the advancements in transdermal delivery of antibiotics.","authors":"Ahlam Zaid Alkilani, Rania Hamed, Batool Musleh, Zaina Sharaire","doi":"10.1080/10717544.2024.2304251","DOIUrl":"10.1080/10717544.2024.2304251","url":null,"abstract":"<p><p>Transdermal drug delivery systems (TDDS) for antibiotics have seen significant advances in recent years that aimed to improve the efficacy and safety of these drugs. TDDS offer many advantages over other conventional delivery systems such as non-invasiveness, controlled-release pattern, avoidance of first-pass metabolism. The objective of this review is to provide an overview on the recent advances in the TDDS of different groups of antibiotics including β-lactams, tetracyclines, macrolides, and lincosamides, utilized for their effective delivery through the skin and to explore the challenges associated with this field. The majority of antibiotics do not have favorable properties for passive transdermal delivery. Thus, novel strategies have been employed to improve the delivery of antibiotics through the skin, such as the use of nanotechnology (nanoparticles, solid-lipid nanoparticles, nanoemulsions, vesicular carriers, and liposomes) or the physical enhancement techniques like microneedles and ultrasound. In conclusion, the transdermal delivery systems could be a promising method for delivering antibiotics that have the potential to improve patient outcomes and enhance the efficacy of drugs. Further research and development are still needed to explore the potential of delivering more antibiotic drugs by using various transdermal drug delivery approaches.</p>","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"31 1","pages":"2304251"},"PeriodicalIF":6.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10802811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139502483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Advances in cell membrane-based biomimetic nanodelivery systems for natural products.","authors":"Yifeng Zhang, Qian Zhang, Chunhong Li, Ziyun Zhou, Hui Lei, Minghua Liu, Dan Zhang","doi":"10.1080/10717544.2024.2361169","DOIUrl":"10.1080/10717544.2024.2361169","url":null,"abstract":"<p><p>Active components of natural products, which include paclitaxel, curcumin, gambogic acid, resveratrol, triptolide and celastrol, have promising anti-inflammatory, antitumor, anti-oxidant, and other pharmacological activities. However, their clinical application is limited due to low solubility, instability, low bioavailability, rapid metabolism, short half-life, and strong off-target toxicity. To overcome these drawbacks, cell membrane-based biomimetic nanosystems have emerged that avoid clearance by the immune system, enhance targeting, and prolong drug circulation, while also improving drug solubility and bioavailability, enhancing drug efficacy, and reducing side effects. This review summarizes recent advances in the preparation and coating of cell membrane-coated biomimetic nanosystems and in their applications to disease for targeted natural products delivery. Current challenges, limitations, and prospects in this field are also discussed, providing a research basis for the development of multifunctional biomimetic nanosystems for natural products.</p>","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"31 1","pages":"2361169"},"PeriodicalIF":6.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141199746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug DeliveryPub Date : 2024-12-01Epub Date: 2024-06-04DOI: 10.1080/10717544.2024.2361165
Qi Chen, Yuyi Zheng, Xuhong Jiang, Yi Wang, Zhong Chen, Di Wu
{"title":"Nature's carriers: leveraging extracellular vesicles for targeted drug delivery.","authors":"Qi Chen, Yuyi Zheng, Xuhong Jiang, Yi Wang, Zhong Chen, Di Wu","doi":"10.1080/10717544.2024.2361165","DOIUrl":"10.1080/10717544.2024.2361165","url":null,"abstract":"<p><p>With the rapid development of drug delivery systems, extracellular vesicles (EVs) have emerged as promising stars for improving targeting abilities and realizing effective delivery. Numerous studies have shown when compared to conventional strategies in targeted drug delivery (TDD), EVs-based strategies have several distinguished advantages besides targeting, such as participating in cell-to-cell communications and immune response, showing high biocompatibility and stability, penetrating through biological barriers, etc. In this review, we mainly focus on the mass production of EVs including the challenges and strategies for scaling up EVs production in a cost-effective and reproducible manner, the loading and active targeting methods, and examples of EVs as vehicles for TDD in consideration of potential safety and regulatory issues associated. We also conclude and discuss the rigor and reproducibility of EVs production, the current research status of the application of EVs-based strategies to targeted drug delivery, clinical conversion prospects, and existing chances and challenges.</p>","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"31 1","pages":"2361165"},"PeriodicalIF":6.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11151811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141237207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Recognizing the biological barriers and pathophysiological characteristics of the gastrointestinal tract for the design and application of nanotherapeutics.","authors":"Shan Li, Tianyu Wu, Jingfeng Wu, Wensheng Chen, Dinglin Zhang","doi":"10.1080/10717544.2024.2415580","DOIUrl":"https://doi.org/10.1080/10717544.2024.2415580","url":null,"abstract":"<p><p>The gastrointestinal tract (GIT) is an important and complex system by which humans to digest food and absorb nutrients. The GIT is vulnerable to diseases, which may led to discomfort or even death in humans. Therapeutics for GIT disease treatment face multiple biological barriers, which significantly decrease the efficacy of therapeutics. Recognizing the biological barriers and pathophysiological characteristics of GIT may be helpful to design innovative therapeutics. Nanotherapeutics, which have special targeting and controlled therapeutic release profiles, have been widely used for the treatment of GIT diseases. Herein, we provide a comprehensive review of the biological barrier and pathophysiological characteristics of GIT, which may aid in the design of promising nanotherapeutics for GIT disease treatment. Furthermore, several typical diseases of the upper and lower digestive tracts, such as <i>Helicobacter pylori</i> infection and inflammatory bowel disease, were selected to investigate the application of nanotherapeutics for GIT disease treatment.</p>","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"31 1","pages":"2415580"},"PeriodicalIF":6.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485891/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug DeliveryPub Date : 2024-12-01Epub Date: 2023-12-26DOI: 10.1080/10717544.2023.2298514
Shengnan Li, Fengmei Li, Yan Wang, Wenqun Li, Junyong Wu, Xiongbin Hu, Tiantian Tang, Xinyi Liu
{"title":"Multiple delivery strategies of nanocarriers for myocardial ischemia-reperfusion injury: current strategies and future prospective.","authors":"Shengnan Li, Fengmei Li, Yan Wang, Wenqun Li, Junyong Wu, Xiongbin Hu, Tiantian Tang, Xinyi Liu","doi":"10.1080/10717544.2023.2298514","DOIUrl":"10.1080/10717544.2023.2298514","url":null,"abstract":"<p><p>Acute myocardial infarction, characterized by high morbidity and mortality, has now become a serious health hazard for human beings. Conventional surgical interventions to restore blood flow can rapidly relieve acute myocardial ischemia, but the ensuing myocardial ischemia-reperfusion injury (MI/RI) and subsequent heart failure have become medical challenges that researchers have been trying to overcome. The pathogenesis of MI/RI involves several mechanisms, including overproduction of reactive oxygen species, abnormal mitochondrial function, calcium overload, and other factors that induce cell death and inflammatory responses. These mechanisms have led to the exploration of antioxidant and inflammation-modulating therapies, as well as the development of myocardial protective factors and stem cell therapies. However, the short half-life, low bioavailability, and lack of targeting of these drugs that modulate these pathological mechanisms, combined with liver and spleen sequestration and continuous washout of blood flow from myocardial sites, severely compromise the expected efficacy of clinical drugs. To address these issues, employing conventional nanocarriers and integrating them with contemporary biomimetic nanocarriers, which rely on passive targeting and active targeting through precise modifications, can effectively prolong the duration of therapeutic agents within the body, enhance their bioavailability, and augment their retention at the injured myocardium. Consequently, these approaches significantly enhance therapeutic effectiveness while minimizing toxic side effects. This article reviews current drug delivery systems used for MI/RI, aiming to offer a fresh perspective on treating this disease.</p>","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"31 1","pages":"2298514"},"PeriodicalIF":6.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10763895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139039671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug DeliveryPub Date : 2024-12-01Epub Date: 2024-06-20DOI: 10.1080/10717544.2024.2361168
Jennifer Huling, Stefan Oschatz, Helge Lange, Katharina Anna Sterenczak, Thomas Stahnke, Jana Markhoff, Oliver Stachs, Steffen Möller, Nasrullah Undre, Anita Peil, Anselm Jünemann, Niels Grabow, Georg Fuellen, Thomas Eickner
{"title":"γ-Cyclodextrin hydrogel for the sustained release of josamycin for potential ocular application.","authors":"Jennifer Huling, Stefan Oschatz, Helge Lange, Katharina Anna Sterenczak, Thomas Stahnke, Jana Markhoff, Oliver Stachs, Steffen Möller, Nasrullah Undre, Anita Peil, Anselm Jünemann, Niels Grabow, Georg Fuellen, Thomas Eickner","doi":"10.1080/10717544.2024.2361168","DOIUrl":"10.1080/10717544.2024.2361168","url":null,"abstract":"<p><p>Glaucoma is the leading cause of blindness worldwide. However, its surgical treatment, in particular via trabeculectomy, can be complicated by fibrosis. In current clinical practice, application of the drug, Mitomycin C, prevents or delays fibrosis, but can lead to additional side effects, such as bleb leakage and hypotony. Previous <i>in silico</i> drug screening and <i>in vitro</i> testing has identified the known antibiotic, josamycin, as a possible alternative antifibrotic medication with potentially fewer side effects. However, a suitable ocular delivery mechanism for the hydrophobic drug to the surgical site does not yet exist. Therefore, the focus of this paper is the development of an implantable drug delivery system for sustained delivery of josamycin after glaucoma surgery based on crosslinked γ-cyclodextrin. γ-Cyclodextrin is a commonly used solubilizer which was shown to complex with josamycin, drastically increasing the drug's solubility in aqueous solutions. A simple γ-cyclodextrin crosslinking method produced biocompatible hydrogels well-suited for implantation. The crosslinked γ - cyclodextrin retained the ability to form complexes with josamycin, resulting in a 4-fold higher drug loading efficiency when compared to linear dextran hydrogels, and prolonged drug release over 4 days.</p>","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"31 1","pages":"2361168"},"PeriodicalIF":6.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11191840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug DeliveryPub Date : 2024-12-01Epub Date: 2024-06-25DOI: 10.1080/10717544.2024.2368971
{"title":"Statement of Retraction: A convergent synthetic platform for dual anticancer drugs functionalized by reduced graphene nanocomposite delivery for hepatocellular cancer.","authors":"","doi":"10.1080/10717544.2024.2368971","DOIUrl":"10.1080/10717544.2024.2368971","url":null,"abstract":"","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"31 1","pages":"2368971"},"PeriodicalIF":6.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11210406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141450119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}